Reloading Prasugrel or Clopidogrel on High Platelet Reactivity Before Percutaneous Coronary Intervention (PRAISE-HPR)
High platelet reactivity unit (PRU) after loading dose clopidogrel in patients undergoing percutaneous coronary intervention (PCI) is related to high risk of short and long term recurrent ischemic events including stent thrombosis.
The investigators hypothesize that additional loading of prasugrel in patients with high PRU after clopidogrel loading would be superior to additional loading of clopidogrel in reducing platelet reactivity and thereby result in lower risk of short term recurrent ischemic events.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
|Official Title:||Comparison of Prasugrel and Clopidogrel Reloading on High Platelet Reactivity in Clopidogrel-loaded Patients Undergoing Percutaneous Coronary Intervention|
- HPR at 24 hours [ Time Frame: 24 hours ] [ Designated as safety issue: No ]Persistently high platelet reactivity after PCI. PRU is measured by methods of VerifyNow device and HPRU is defined as PRU of 240 or more.
- MACE [ Time Frame: 30 days (1 month) ] [ Designated as safety issue: No ]Major adverse cardiovascular events consist of cardiac death, myocardial infarction, stroke, stent thrombosis, cardiac enzyme (CRP, CK-MB, Troponin-I)
- Bleeding [ Time Frame: 30 days (1 month) ] [ Designated as safety issue: No ]Major, minor or minimal bleeding defined by TIMI(thrombolysis in myocardial infarction) bleeding criteria
- HPRs [ Time Frame: 4 hours after PCI, 30 days after PCI ] [ Designated as safety issue: No ]Persistently high platelet reactivity 4 hours and 30 days after PCI. PRU is measured by methods of VerifyNow device and HPRU is defined as PRU of 240 or more.
|Study Start Date:||September 2012|
|Estimated Study Completion Date:||January 2015|
|Estimated Primary Completion Date:||December 2014 (Final data collection date for primary outcome measure)|
Reloading with prasugrel 20mg & followed by administration of 5mg/day for 30 days
Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
Other Name: Effient
Active Comparator: Clopidogrel
Reloading with clopidogrel 300mg and followed by administration of clopidogrel 75 mg/day for 30 days
Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
Other Name: Plavix
Dual antiplatelet therapy with acetylsalicyclic acid (ASA) and additional clopidogrel is now standard regimen for the prevention of recurrent ischemic events in patients who undergo PCI.
But decreased effect of clopidogrel in a group of patients was reported and they are known to be associated with high risk of recurrent ischemic event. Decreased effect of clopidogrel is mainly resulted from decreased function to metabolite prodrug, clopidogrel to active form of drug.
Prasugrel, newer thienopyridine has been recently developed and showed advantages to clopidogrel. Prasugrel is known to have shorter onset time to achieve steady state level than clopidogrel and constant pharmacologic effect regardless of patient diversity.
High PRU after loading dose clopidogrel in patients undergoing PCI is known to be related to increased risk of short and long term recurrent ischemic events including stent thrombosis. Prasugrel has been reported to be effective in reducing platelet reactivity in patients showing resistance to clopidogrel and high PRU.
The investigators hypothesize that additional loading of prasugrel in patients with high PRU after clopidogrel loading would be superior to additional loading of clopidogrel in reducing platelet reactivity and thereby result in reduced risk of short term recurrent ischemic events.
The investigators plan to include 70 acute coronary syndrome patients who are planned to undergo PCI and show high platelet reactivity. Most patients with ACS administer loading dose of ASA and clopidogrel as soon as they are assumed to be ACS.
The investigators plan to perform platelet reactivity test by VeryfyNow (VN) before PCI and enroll patients with high PRU defined by 240 or more. They are to randomly administered additional 300mg of clopidogrel or 20mg of prasugrel.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01609647
|Contact: Moo Hyun Kim, MDfirstname.lastname@example.org|
|Contact: Dong Hyun Lee, MDemail@example.com|
|Korea, Republic of|
|DongA University Hospital||Recruiting|
|Busan, Korea, Republic of, 602-715|
|Contact: Moo Hyun Kim, MD +82-51-240-2976 firstname.lastname@example.org|
|Principal Investigator:||Moo Hyun Kim, MD||Director, Regional Clinical Trial Center|